Scarica l'app Stockscreener
10.29
5.30%
0.55
Precedente Chiudi:
$9.74
Aprire:
$9.63
Volume 24 ore:
962.56K
Relative Volume:
0.39
Capitalizzazione di mercato:
$716.99M
Reddito:
-
Utile/perdita netta:
$-297.11M
Rapporto P/E:
-1.9827
EPS:
-5.19
Flusso di cassa netto:
$-216.95M
1 W Prestazione:
+18.70%
1M Prestazione:
+11.72%
6M Prestazione:
+90.28%
1 anno Prestazione:
-12.72%
Intervallo 1D:
$9.525
$10.35
Intervallo di 1 settimana:
$8.025
$10.35
Portata 52W:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
10.27 | 615.79M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.04 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
439.48 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.63 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals Reports Strong Q2 Growth - TipRanks
Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth - MSN
Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript - Insider Monkey
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $17 to $28 - 富途牛牛
Phathom 2025 Q2 Earnings Net Loss Narrows 17.1% - AInvest
Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Q2 2025: Unpacking Contradictions in Growth Strategies and Market Focus - AInvest
Phathom Pharmaceuticals Stock (PHAT) Opinions on Q2 2025 Earnings Report - Quiver Quantitative
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat - Investing.com Canada
Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations - Investing.com Australia
Phathom Pharmaceuticals (PHAT) Q2 Earnings: Revenue Surpasses Es - GuruFocus
Phathom Pharmaceuticals Q2 2025 Financial Results - TradingView
Phathom Pharmaceuticals' Strategic Restructuring and Market Position: A Pathway to Long-Term Value Creation in a Capital-Constrained Biopharma Landscape - AInvest
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Published on: 2025-08-04 08:41:19 - metal.it
Does Phathom Pharmaceuticals Inc. stock perform well during market downturnsOutstanding trading profits - Jammu Links News
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
Is it the right time to buy Phathom Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
How does Phathom Pharmaceuticals Inc. generate profit in a changing economySkyrocketing investment returns - Jammu Links News
Should I hold or sell Phathom Pharmaceuticals Inc. stock in 2025Achieve impressive returns with smart timing - Jammu Links News
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Unlock exclusive stock market insights - Jammu Links News
When is Phathom Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News
What is the dividend policy of Phathom Pharmaceuticals Inc. stockBuild wealth steadily with proven strategies - Jammu Links News
What catalysts could drive Phathom Pharmaceuticals Inc. stock higher in 2025Free Stock Market Real-Time Monitoring - Jammu Links News
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News - 富途牛牛
Published on: 2025-08-01 16:17:13 - metal.it
Elliott Wave Theory Predicts Pullback in Phathom Pharmaceuticals Inc.Low Risk Picks for Daily Trading Released - metal.it
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
What are the latest earnings results for Phathom Pharmaceuticals Inc.High-octane financial growth - Jammu Links News
What are the technical indicators suggesting about Phathom Pharmaceuticals Inc.Robust investment performance - Jammu Links News
Phathom Pharmaceuticals To Report Second Quarter 2025 Financial Results And Provide Business Update On Thursday, August 7, 2025 - TradingView
Phathom Pharmaceuticals to Host Conference Call for Q2 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025 - The Manila Times
Phathom Pharmaceuticals to Reveal Q2 2025 Performance: Key Updates on VOQUEZNA Sales Expected - Stock Titan
What is Phathom Pharmaceuticals Inc. company’s growth strategyInvest with confidence backed by data - Jammu Links News
What makes Phathom Pharmaceuticals Inc. stock price move sharplyFree Real-Time Market Predictions - metal.it
What is the risk reward ratio of investing in Phathom Pharmaceuticals Inc. stockMaximize profits with strategic stock selection - jammulinksnews.com
When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Turn A Profit? - 富途牛牛
What analysts say about Phathom Pharmaceuticals Inc. stockFree Capital Allocation Plans - jammulinksnews.com
Is Phathom Pharmaceuticals Inc. a good long term investmentFree Daily Trading Room Entry - Jammu Links News
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
| Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
| Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
3.48%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):